Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 3908389, 13 pages
Review Article

Multipotent Mesenchymal Stem Cell Treatment for Discogenic Low Back Pain and Disc Degeneration

1Southwest Spine & Sports, 9913 N. 95th Street, Scottsdale, AZ 85258, USA
2iOrthoBiologix, 12312 Copper Way, Charlotte, NC 28277, USA
3Harborview Medical, 6151 Thorton Avenue, Suite 200, Des Moines, IA 50321, USA

Received 8 June 2015; Accepted 18 October 2015

Academic Editor: Shimon Slavin

Copyright © 2016 Jeffrey Zeckser et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Low back pain with resultant loss of function, decreased productivity, and high economic costs is burdensome for both the individual and the society. Evidence suggests that intervertebral disc pathology is a major contributor to spine-related pain and degeneration. When commonly used conservative therapies fail, traditional percutaneous or surgical options may be beneficial for pain relief but are suboptimal because of their inability to alter disc microenvironment catabolism, restore disc tissue, and/or preserve native spine biomechanics. Percutaneously injected Multipotent Mesenchymal Stem Cell (MSC) therapy has recently gained clinical interest for its potential to revolutionarily treat disc-generated (discogenic) pain and associated disc degeneration. Unlike previous therapies to date, MSCs may uniquely offer the ability to improve discogenic pain and provide more sustained improvement by reducing disc microenvironment catabolism and regenerating disc tissue. Consistent treatment success has the potential to create a paradigm shift with regards to the treatment of discogenic pain and disc degeneration.